Mounting evidence has shown that treatments with anti-HER2 mAbs that are effective in breast cancers may not be effective in gastric cancers [25], emphasizing the difference between the two cancers and the need for distinct strategies for their treatment. This evidence concerns the gene ERBB2 and cancer.